July 20, 2021
Թϴͷ Co., Ltd. (Թϴͷ) is jointly developing new drugs for neglected tropical diseases with the Drugs for Neglected Diseases initiative (DNDi), an international non-profit organization. Թϴͷ’s CEO Haruo Naito participated in DNDi’s online event “Deliver 18 new treatments by 2028 – The future of partnerships and role of Japan” which was held on June 30, 2021. Currently, Թϴͷ and DNDi are jointly developing Թϴͷ’s in-house discovered antifungal agent fosravuconazole (E1224) as a treatment for mycetoma, a neglected tropical disease. Furthermore, Թϴͷ and DNDi have established a long-term partnership and are collaborating on other neglected tropical diseases such as leishmaniasis.

DNDi has announced a new strategic plan aiming to deliver 18 new treatments by 2028 in collaboration with partners. A panel of leaders and experts of industry, government and academia including Թϴͷ’s Naito discussed what Japan can do for neglected patients and what is needed for future R&D partnerships. Please visit to watch the event.

Թϴͷ will continue to work on developing new drugs for neglected tropical diseases such as mycetoma and leishmaniasis with its global partners, including DNDi.
〶〶
〶〶
Share